Have melatonin and melatonin-receptor agonists been studied for safety and efficacy in elderly patients both with and without dementia?

Melatonergic Medications in Elderly Patients: Evidence Summary

Yes, melatonergic medications have been extensively studied in elderly patients both with and without dementia, with melatonin showing more consistent benefits than ramelteon, particularly for postoperative delirium prevention and sleep disturbances in dementia.

Evidence in Elderly Without Dementia

Insomnia Treatment

The 2016 American College of Physicians guideline 1 evaluated both melatonin and ramelteon for insomnia in general and older populations:

• Melatonin (2 mg prolonged release): One moderate-quality RCT (n=791) showed insufficient evidence for global and sleep outcomes, with small effect sizes and no difference in adverse effects compared to placebo 1

• Ramelteon (4-16 mg): Five moderate-quality RCTs (n=3124) demonstrated that ramelteon did not reduce sleep variables compared to placebo (low-strength evidence). In older adults specifically, ramelteon improved sleep onset latency by only 10 minutes without improving total sleep time 1. Notably, 58% of older adults withdrew from ramelteon studies, though adverse effects were common but rarely severe 1

Postoperative Delirium Prevention

The most compelling evidence for melatonergic medications in elderly patients comes from postoperative delirium prevention studies:

The 2026 meta-analysis 2 of 16 RCTs (n=2115) showed:

• Melatonin reduced postoperative delirium from 31.4% to 22.4% (RR 0.67, p=0.004)
• Doses ≥5 mg were most effective, reducing delirium from 36.7% to 18.2% (RR 0.52, p<0.001)
• Ramelteon showed no benefit (15.1% vs 14.9%, RR 0.98, p=0.948)

This is corroborated by the 2024 meta-analysis 3 (13 RCTs, n=2086) showing melatonin reduced delirium incidence (OR=0.59, p<0.01), particularly in surgical patients (OR=0.60, p=0.01), with no effect on mortality or length of stay.

Evidence in Elderly With Dementia

Sleep Disturbances

For dementia-related sleep problems, melatonin demonstrates modest but meaningful benefits 4:

A 2015 meta-analysis of 7 RCTs (n=520) in patients with dementia showed:

• Total sleep time increased by 24.36 minutes (p=0.02)
• Sleep efficiency marginally improved (p=0.07), with stronger effects when treatment exceeded 4 weeks (p=0.02)
• No severe adverse events reported
• No improvement in cognitive function

Cognitive Function

The evidence for cognitive benefits is mixed:

• The 2015 meta-analysis 4 found no significant cognitive improvement in dementia patients despite sleep improvements
• However, a 2025 meta-analysis 5 of 8 RCTs (n=518) in adults with cognitive impairment showed melatonin significantly improved cognitive function (MD: 1.08, p<0.0001), with strongest effects when:
  • Administered for 13-24 weeks (MD: 2.04, p<0.00001)
  • Given between 20:30-21:00 (MD: 2.2, p<0.00001)
  • Used in mild cognitive impairment specifically (MD: 2.63, p<0.000001)

Safety Considerations

Key Safety Points:

• Melatonin: Generally well-tolerated with no difference in adverse effects versus placebo across multiple studies 1, 3, 4
• Ramelteon: FDA labeling warns of cognitive/behavioral abnormalities, complex behaviors (sleep driving), and exacerbation of depression in depressed patients 1
• Benzodiazepines: Observational data shows association with dementia, particularly with higher doses and long half-life agents 1

Clinical Algorithm

For elderly patients with insomnia:

1. If postoperative setting: Use melatonin ≥5 mg perioperatively
2. If chronic insomnia without dementia: Evidence is weak; melatonin 2 mg may be tried but expect minimal benefit
3. Avoid ramelteon as first-line (no demonstrated efficacy in elderly)

For elderly patients with dementia and sleep disturbances:

1. Use melatonin for ≥4 weeks to improve sleep efficiency and total sleep time
2. Administer between 20:30-21:00 for optimal effect
3. Do not expect cognitive improvement unless patient has mild cognitive impairment (not advanced dementia)
4. For MCI patients: Consider 13-24 week trial for potential cognitive benefits

Important Caveats

• The certainty of evidence for postoperative delirium prevention is rated low due to moderate-to-high heterogeneity 2
• Dose-response effects (≥5 mg superiority) should be interpreted cautiously given study heterogeneity 2
• The divergence between melatonin and ramelteon efficacy is striking and consistent across multiple outcomes 1, 2, 6
• Most cognitive benefit studies enrolled patients with MCI rather than established dementia 5